Clinical Trial Results: A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

Phase 4 trial results for baricitinib in rheumatoid arthritis have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2026-06-24